CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
Por:
Moreno-Manuel, A, Jantus-Lewintre, E, Simoes, I, Aranda, F, Calabuig-Farinas, S, Carreras, E, Zuniga, S, Saenger, Y, Rosell, R, Camps, C, Lozano, F and Sirera, R
Publicada:
1 ago 2020
Resumen:
Background: The study of immune surveillance in the tumour microenvironment is leading to the development of new biomarkers and therapies. The present research focuses on the expression of CD5 and CD6-two lymphocyte surface markers involved in the fine tuning of TCR signaling-as potential prognostic biomarkers in resectable stages of non-small cell lung cancer (NSCLC).
Methods: CD5 and CD6 gene expression was analysed by reverse transcription quantitative polymerase chain reaction (RTqPCR) in 186 paired fresh frozen tumour and normal tissue samples of resected NSCLC.
Results: Patients with higher CD5 expression had significantly increased overall survival (OS, 49.63 vs. 99.90 months, P=0.013). CD5 expression levels were correlated to CD4 infiltration and expression levels, and survival analysis showed that patients with a higher CD5/CD4(+) ratio had significantly improved prognosis. Multivariate analysis established CD5 expression as an independent prognostic biomarker for OS in early stages of NSCLC (HR=0.554; 95% CI, 0.360-0.853; P=0.007). Further survival analysis of NSCLC cases (n=97) from The Cancer Genome Atlas (TCGA) database, confirmed the prognostic value of both CD5 and CD6 expression, although CD6 expression alone did not reach significant prognostic value in our NSCLC training cohort.
Conclusions: Our data support further studies on CD5 and CD6 as novel prognostic markers in resectable NSCLC and other cancer types (i.e., melanoma), as well as a role for these receptors in immune surveillance.
Filiaciones:
Moreno-Manuel, A:
Hosp Gen Univ Valencia, Mol Oncol Lab, Fdn Invest, Valencia, Spain
Hosp Gen Univ Valencia, Ctr Invest Principe Felipe, TRIAL Mixed Unit, Fdn Invest, Valencia, Spain
Jantus-Lewintre, E:
Hosp Gen Univ Valencia, Mol Oncol Lab, Fdn Invest, Valencia, Spain
Hosp Gen Univ Valencia, Ctr Invest Principe Felipe, TRIAL Mixed Unit, Fdn Invest, Valencia, Spain
Univ Politecn Valencia, Dept Biotechnol, Camino Vera S-N, Valencia 46022, Spain
CIBERONC, Valencia, Spain
Simoes, I:
Inst Invest Biomed August Pi i Sunyer, Immunoreceptors Innate & Adaptat Syst, Barcelona, Spain
Aranda, F:
Inst Invest Biomed August Pi i Sunyer, Immunoreceptors Innate & Adaptat Syst, Barcelona, Spain
Calabuig-Farinas, S:
Hosp Gen Univ Valencia, Ctr Invest Principe Felipe, TRIAL Mixed Unit, Fdn Invest, Valencia, Spain
CIBERONC, Valencia, Spain
Univ Valencia, Dept Pathol, Valencia, Spain
Carreras, E:
Inst Invest Biomed August Pi i Sunyer, Immunoreceptors Innate & Adaptat Syst, Barcelona, Spain
Zuniga, S:
INCLIVA, Unidad Med Precis Oncol Traslac, Valencia, Spain
Saenger, Y:
Columbia Univ Coll Phys & Surg, Dept Med, New York, NY USA
:
Germans Trias & Pujol Hlth Sci Inst & Hosp, Catalan Inst Oncol, Badalona, Spain
Camps, C:
Hosp Gen Univ Valencia, Mol Oncol Lab, Fdn Invest, Valencia, Spain
Hosp Gen Univ Valencia, Ctr Invest Principe Felipe, TRIAL Mixed Unit, Fdn Invest, Valencia, Spain
CIBERONC, Valencia, Spain
Univ Valencia, Dept Med, Valencia, Spain
Consorcio Hosp Gen Univ Valencia, Serv Oncol Med, Valencia, Spain
Lozano, F:
Inst Invest Biomed August Pi i Sunyer, Immunoreceptors Innate & Adaptat Syst, Barcelona, Spain
Hosp Clin Barcelona, Ctr Diagnost Biomed, Serv Immunol, Barcelona, Spain
Univ Barcelona, Fac Med, Dept Biomed, Barcelona, Spain
Sirera, R:
Hosp Gen Univ Valencia, Mol Oncol Lab, Fdn Invest, Valencia, Spain
Hosp Gen Univ Valencia, Ctr Invest Principe Felipe, TRIAL Mixed Unit, Fdn Invest, Valencia, Spain
Univ Politecn Valencia, Dept Biotechnol, Camino Vera S-N, Valencia 46022, Spain
CIBERONC, Valencia, Spain
Green Published, gold
|